Skip to content
Review Open access

Advances in Targeting Central Cholinergic Dysfunction for Neurodegenerative Diseases: From Pharmacotherapy to Neuromodulation

Sep 2026 · CNS Neuroscience & Therapeutics · Vol 32 · 0 citations · 218 references
Medicine

TL;DR

The integration of sophisticated pharmacological agents with circuit‐level neuromodulation represents the next frontier in treating cholinergic dysfunction across the spectrum of neurodegenerative disorders, advancing the therapeutic goal from chemical enhancement to circuit repair and regeneration.

Abstract

ABSTRACT Background The central cholinergic system has long been a cornerstone therapeutic target for neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB). For decades, acetylcholinesterase inhibitors (AChEIs) have served as the standard symptomatic treatment, providing cognitive and functional relief by enhancing synaptic acetylcholine levels. However, their limited efficacy and inability to modify disease progression underscore the fundamental constraint of purely neurochemical enhancement, especially in the context of progressive cholinergic neuron loss. Results and Conclusion This review critically examines the evolution of cholinergic therapies beyond AChEIs. We first explore the shift from broad neurotransmitter enhancement toward precision targeting of receptor subtypes and the development of multi‐target pharmacological strategies. Furthermore, we highlight how neuromodulation techniques—including vagus nerve stimulation, deep brain stimulation, and non‐invasive brain stimulation—directly engage and restore dysfunctional neural circuits, moving beyond mere chemical enhancement. Emerging directions such as advanced cholinergic imaging, gene therapy, and cell‐based regeneration are also discussed as promising pathways toward true disease modification. Ultimately, the integration of sophisticated pharmacological agents with circuit‐level neuromodulation represents the next frontier in treating cholinergic dysfunction across the spectrum of neurodegenerative disorders, advancing the therapeutic goal from chemical enhancement to circuit repair and regeneration.

Read PDF

Similar papers

Review Aug 2026

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Alzheimer’s Disease (AD) is a neurodegenerative disorder with progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress, and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...

Lalit Parihar, A. Singh, Sanjar Alam · 0 citations
Open access Aug 2026

Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders

Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...

Nisha, Sumairah Qadir · 0 citations
Review Open access Aug 2026

Advances and Challenges in Alzheimer's Disease: a Comprehensive Review of Treatment Strategies, Diagnostic Tools, and Future Directions

"Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, primarily caused by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain". Current therapeutic strategies focus on symptomatic relief, with acetylcholinesterase (AChE) i...

Sushma, Rishab Dubey, Rupa Chaturvedi et al. · 0 citations
Review Open access Sep 2026

Synaptic Plasticity and Cognitive Enhancement: Bridging Neuropathological Cognitive Disorders to Emerging Neuropharmacological Strategies

Synaptic plasticity refers to the fundamental process through which synaptic connections become stronger or weaker in response to experience, thereby forming the basis of learning and memory. Disruption of this process is increasingly regarded as a common underlying mechanism of several cognitive and neuropsychiatric d...

S. M. Alqahtani · 0 citations
Review Sep 2026

Crosstalk and Convergence in Alzheimer's Disease: Integrating Brain Injury, Neuroinflammation, and Precision Medicine for Next-Generation Therapeutics.

Alzheimer's Disease (AD) is a complex disorder whose underlying biology is not fully explained by traditional single-pathway models. For several decades, research has largely focused on the roles of amyloid-β and tau in the formation and deposition of plaques and neurofibrillary tangles associated with AD pathology and...

Desh Deepak Singh · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.